NVCR News and Press, NovoCure Limited From 04/13/21

NovoCure Limited (NVCR) +62% after DMC recommends shorter phase 3 NSCLC trial.Mackinac Financial Corporation (MFNC) +31% on merger agreement with Nicolet Bankshares.Dragon Victory International Limited (LYL) +44%.Optibase (OBAS) +20%.Tian Ruixiang Holdings Ltd (TIRX) +26%.vTv Therap...

Novocure (NVCR) shares are up more than 81% in premarket trading after a data monitoring committee (DMC) recommended a reduced trial duration and patient numbers in its phase 3 trial for its Tumor Trial Fields (TTF) treatment for non-small cell lung cancer.The DMC told Novocure that...

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial SHANGHAI and SAN FRAN...

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial Novocure (NASDA...

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021. Research spanning seven s...

NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells. The company is working to expand use cases via FDA approval, which could drive growth for years to come. The stock isn't "cheap" but...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q4 2020 Earnings Call Transcript

Shares of NovoCure (NASDAQ: NVCR) were sinking 12.5% lower as of 3 p.m. EST on Thursday. The decline came after the company delayed several clinical studies and Evercore ISI analyst Vijay Kumar wrote to clients that NovoCure's growth is set to taper off. Kumar's gloomy predictio...

NovoCure Limited. (NVCR) Q4 2020 Results Earnings Conference Call February 25, 2021, 08:00 AM ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medica...